Table 2.
Characteristic of the 17 included studies.
| Ref. | Abudu et al. [12] | Bacci et al. [13] | Bacci et al.b[14] | Bramer et al. [15] | Ferguson et al. [16] | Guo et al. [17] | Hegyi et al. [18] | Jiang et al. [19] | Kim et al. [20] |
|---|---|---|---|---|---|---|---|---|---|
| Country | England | Italy | Italy | UK | Canada | China | Hungary | China | Korea |
| Patient Number | 40 | 46 | 560 | 56 | 31 | 21 | 122 | 64 | 37 |
| LSS, | 27 | 35 | 95 | 44 | 19 | 13 | 92 | 32 | 3 |
| Amputation | 13 | 11 | 465 | 12 | 12 | 8 | 30 | 32 | 4 |
| Study period | 1975–1994 | 1983–1999 | 1983–1995 | 1983–2003 | 1989–2006 | 1998–2008 | 1988–2006 | 2001–2011 | – |
| Male | 25 | 24 | 320 | 36 | 14 | 14 | 65 | 46 | 26 |
| Female | 14 | 22 | 240 | 20 | 17 | 7 | 57 | 18 | 11 |
| Median age(range), years | 18 (2–46) | 11 (3–20) | – | 16 (4–57) | 30 (11–8) | 14.5 (9–17) | 13.8±3.6a | 18.4±6.3 (12–30) | – |
| Enneking stage | Stage-IIB | Stage-IIB | – | – | – | Stage-IIA, Stage-IIB | – | Stage-IIA, Stage-IIB | – |
| Follow-up(range), months | 55 (8–175) | 132 (36–240) | 22.6 (3–96) | 117 (7–252) | – | 38 (28–62) | – | 8–42 | 43 (10–228) |
| Poor chemotherapy | – | 12 (26%) | 194 (35%) | 43 (78%) | – | – | 67 (55%) | – | 23 (62%) |
| Local recurrence | |||||||||
| LSS | 5 | 1 | 6 | 6 | 2 | 2 | – | 2 | 4 |
| Amputation | 0 | 1 | 20 | 2 | 0 | – | – | 2 | 0 |
| 5-year Survival | |||||||||
| LSS | 17 | – | 60 | – | – | 9 | 58 | 25 | – |
| Amputation | 6 | – | 230 | – | – | 3 | 23 | 19 | – |
| Metastatic occurrence | |||||||||
| LSS | 12 | – | – | – | – | 1 | – | – | – |
| Amputation | 9 | – | – | – | – | 4 | – | – | – |
| Ref. | Ma et al. [21] | Mavrogenis et al. [22] | Niu et al. [23] | Robert et al. [24] | Scully et al. [25] | Xu et al. [26] | Zhang et al. [27] | Zhao et al. [28] |
| Country | China | Italy | China | USA | USA | China | China | China |
| Patient Number | 51 | 42 | 22 | 57 | 52 | 58 | 31 | 53 |
| LSS, | 32 | 23 | 12 | 33 | 30 | 43 | 17 | 37 |
| Amputation | 19 | 19 | 10 | 24 | 22 | 15 | 14 | 16 |
| Study period | 1991–1999 | 1985–2010 | 1992–2001 | 2007–2008 | 1977–1996 | 1992–2002 | – | 1996–2007 |
| Male | 35 | 23 | 15 | 20 | 28 | 30 | 26 | – |
| Female | 16 | 19 | 7 | 37 | 24 | 28 | 5 | – |
| Median Age(range), years | 22.3 (10–47)a | 26 (7–78)a | 18 (3–36) | 33.8 (16.1–52) | 23±17.4a | 20.26 (12–55) | 17a | 19.5 (5–45)a |
| Enneking stage | – | Stage-IIA, Stage-IIB | Stage-IIB | – | Stage-IIB | Stage-IIB | Stage-IIA, Stage-IIB | Stage-IIA, Stage-IIB |
| Follow-up(range), months | 72 (60–144) | 60 (8–288) | 54.7 (8–146) | 223.2 (39.6–338.4) | 54 (6–152.4) | 129.6 (72–192) | 43.2 | – |
| Poor chemotherapy | – | 7 (17%) | – | – | 29 (64%) | – | – | – |
| Local recurrence | ||||||||
| LSS | 2 | 5 | 2 | – | 7 | 7 | 5 | 3 |
| Amputation | – | 2 | 1 | – | 4 | 1 | 12 ( | 1 |
| 5-year Survival | ||||||||
| LSS | 12 | – | 8 | – | 19 | 19 | 6 | 19 |
| Amputation | 7 | – | 4 | – | 12 | 8) | 1 | |
| Metastatic Occurrence | ||||||||
| LSS | – | 1 | 3 | – | – | – | ||
| Amputation | – | 3 | 6 | – | – | – |